1	Supplementary Online Content
2	
3 4 5	Saccone G, Maruotti GM, Giudicepietro A, Martinelli P. Effect of cervical pessary on spontaneous preterm birth in women with singleton pregnancies and short cervical length: a randomized clinical trial. <i>JAMA</i> . doi:10.1001/jama.2017.18956
6	
7 8 9	 eTable 1. Results of Vaginal Swabs at Randomization eTable 2. Post Hoc Secondary Outcomes eTable 3. Subgroup Analyses for Spontaneous Preterm Birth at Less Than 34 Weeks
10	
11 12	This supplementary material has been provided by the authors to give readers

- 12 additional information about their work.
- 13
- 14

15 eTable 1. Results of Vaginal Swabs at Randomization

16

Vaginal swabs		y group =150	Control group N=150		
Positive vaginal swab at randomization n	36 (24.0%)		41 (27.3%)		
(%)Antibiotics for positive vaginal swab n (%)33 (22.0		22.0%)	38 (2	25.3%)	
Abnormal results	n	Antibiotic therapy	n	Antibiotic therapy	
		n		n	
Bacterial vaginosis	30	30	34	34	
Candida	3	0	3	0	
Escherichia coli	1	1	2	2	
Ureoplasma	1	1	1	1	
Group B streptococcus	1	1	1	1	

19

¹⁷ 18 Data are presented as number (percentage).

20 eTable 2. Post Hoc Secondary Outcomes

21

	Pessary group N=150	Control group N=150	Between group difference in % (95% CI)	RR (95% CI)	p-value***
Overall preterm birth	35 (23.3%)	53 (35.3%)	-12.0 (-22.5 to -1.2)	0.66 (0.46 to 0.95)	0.03
<37 weeks					
Overall preterm birth	14 (9.3%)	26 (17.3%)	-8.0 (-16.1 to -0.1)	0.54 (0.29 to 0.99)	0.04
<34 weeks					
Overall preterm birth	11 (7.3%)	15 (10.0%)	-2.7 (-4.2 to +9.7)	0.73 (0.35 to 1.54)	0.54
<32 weeks					
Overall preterm birth	7 (4.7%)	9 (6.0%)	-1.3 (-4.4 to +7.1)	0.78 (0.30 to 2.03)	0.80
<28 weeks					
Iatrogenic preterm birth <34 weeks	3 (2.0%)*	3 (2.0%)**	0 (-4.1 to +4.1)	1.00 (0.21 to 4.88)	1.00
Birth weight <2,500	28 (18.7%)	45 (30.0%)	-11.3 (-1.1 to +21.2)	0.62 (0.41 to 0.94)	0.03
grams					
Birth weight <1,500	10 (6.7%)	15 (10.0%)	-3.3 (-3.5 to +10.2)	0.67 (0.31 to 1.44)	0.40
grams					
Necrotizing enterocolitis	3 (2.0%)	4 (2.7%)	-0.7 (-3.5 to +5.0)	0.75 (0.17 to 3.29)	0.99
Intraventricular	4 (2.7%)	6 (4.0%)	-1.3 (-3.5 to +6.2)	0.67 (0.19 to 2.31)	0.75
hemorrhage grade 3	× ,	, , , , , , , , , , , , , , , , , , ,	· · · ·	· · · · ·	
or 4					
Respiratory distress	14 (9.3%)	31 (20.7%)	-11.4 (-19.9 to -2.9)	0.45 (0.25 to 0.81)	0.01
syndrome					
Bronchopulmonary	8 (5.3%)	12 (8.0%)	-2.7 (-3.5 to +9.0)	0.67 (0.28 to 1.58)	0.49
dysplasia					
Retinopathy of prematurity	1 (0.7%)	9 (6.0%)	-5.3 (-10.4 to -0.9)	0.11 (0.01 to 0.87)	0.02
requiring therapy					
Blood-culture proven	9 (6.0%)	13 (8.7%)	-2.7 (-3.8 to +9.3)	0.69 (0.31 to 1.57)	0.50
sepsis					

22

23 Data are presented as number (percentage).

24 RR, relative risk; CI, confidence interval; Overall preterm birth, either spontaneous or indicated 25 preterm birth

26 No adjustment for multiple comparisons was made, so the findings of the secondary outcomes

should be considered exploratory. 27

28 Boldface data, statistically significant

29 *One for nonreassuring fetal heart rate at nonstress test, and two for preeclampsia

**One for intrauterine growth restriction, and two for preeclampsia 30

*** chi-square test with continuity correction 31

32

33	eTable 3	Subgroup	Analyses f	for Spontaneou	is Preterm Birth	at Less Than 34 Weeks
55	crabic J.	Subgroup I	mary ses 1	101 Spontaneou	as I fotorin Dhu	at Loss Than 5+ Weeks

34

	Pessary group	Control group	Between group difference % (95%	RR (95% CI)	p-value*	Test of interaction
			CI)			p-value**
Progesterone	10/133 (7.5%)	21/125 (16.8%)	-9.3 (-17.7 to -1.0)	0.45 (0.22 to 0.91)	0.04	
therapy						0.56
No	1/17 (5.9%)	2/25 (8.0%)	-2.1 (-21.8 to +21.0)	0.74 (0.07 to 7.48)	0.99	
progesterone						
therapy						
TVU CL	3/56 (5.4%)	10/42 (23.8%)	-18.4 (-34.6 to -3.3)	0.23 (0.07 to 0.77)	0.02	
≤10mm						0.46
TVU CL	8/94 (8.5%)	13/108 (12.0%)	-3.5 (-5.8 to +12.5)	0.71 (0.31 to 1.63)	0.56	
>10mm						

35

36 Data are presented as number/total number (percentage).

37 Boldface data, statistically significant

38 SPTB, spontaneous preterm birth; RR, relative risk; CI, confidence interval; TVU CL,

39 transvaginal ultrasound cervical length

40 * chi-square test with continuity correction

41 **Wald test

42

43

44